Ionis Pharmaceuticals (NASDAQ: IONS) CEO Brett Monia participated in a fireside chat Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, disclosing TRYNGALZA (olezarsen, an antisense oligonucleotide that reduces apolipoprotein C-III production and lowers triglycerides) H1 2026 U.S. net product sales of $32 million (Q2 alone was $5 million) with full-year 2026 guidance of $100-110 million. The severe hypertriglyceridemia (sHTG) launch followed June 2026 FDA approval and represents the first indication expansion from the initial familial chylomicronemia syndrome (FCS) indication. Ionis raised peak sales guidance in the sHTG indication from $1 billion-plus to $2 billion-plus. The sHTG marketing application is under review in the European Union with potential launch in 2027. Ionis is also commercializing the September 3, 2026 FDA-approved ZANVASTRO (zilganersen, an antisense oligonucleotide) for Alexander disease, a first-in-class disease-modifying therapy for a rare progressive neurodegenerative disorder with no other approved therapies. The company acknowledged parallel setbacks in cardiovascular studies including the Novartis pelacarsen Phase 3 Lp(a)HORIZON miss reported September 4.
Takeda (NYSE: TAK) confirmed Sunday August 30, 2026 that commercial launch of Mimrylo (rusfertide, the first-in-class subcutaneous hepcidin mimetic peptide approved Friday August 28 for erythrocytosis in adults with polycythemia vera) is underway across the U.S., with the product available at specialty pharmacies within 48 hours of FDA approval. The commercial launch approach reflects Takeda's rare-blood-cancer specialty commercial infrastructure built up around Iclusig (ponatinib) for chronic myeloid leukemia and the recent Fruzaqla (fruquintinib) launch in colorectal cancer. Jefferies analyst projections of $2 billion peak sales assume rapid coverage decisions from major U.S. payers by end of 2026 plus European approval on the same clinical dataset in H1 2027. The Mimrylo launch establishes the hepcidin mimetic peptide category and sets a commercial template that Disc Medicine's DISC-0974 (an anti-hemojuvelin antibody targeting hepcidin from a different angle) and Silence Therapeutics' SLN124 (siRNA targeting TMPRSS6, an upstream hepcidin regulator) will need to differentiate against.
Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.